This study tests whether adding the experimental drug LAM561 to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, a fast-growing brain tumor. About 144 adults aged 18 to 75 will receive either LAM561 or a placebo alongside their usual treatmen…
Phase: PHASE2, PHASE3 • Sponsor: Laminar Pharmaceuticals • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC